{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:15:12Z","timestamp":1785420912110,"version":"3.56.0"},"reference-count":19,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences, K.K."},{"id":[{"id":"https:\/\/ror.org\/01fk6s398","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Early initiation of remdesivir (RDV) is recommended to improve COVID-19 outcomes, but real-world studies describing patterns of RDV use and related outcomes among Japanese COVID-19 patients at high-risk of severe outcomes or death are limited. This claims-based cohort study included 60,165 high-risk patients hospitalized with COVID-19 between October 2021 and June 2023 using the DeSC Healthcare claims database. Patients were categorized into early-RDV (within 2 days of hospital admission), late-RDV (between day 3 and day 7), and no-RDV groups based on RDV initiation timing. Descriptive analyses were performed according to RDV groups. Of the study patients, \u226585% were very elderly (\u226575 years). Approximately 39% of patients received early RDV, 2% received late RDV, and 59% received no RDV. By day 28, the proportion of alive discharge for early-, late-, and no-RDV groups was 74.9%, 63.1%, and 71.8%, respectively. The mortality for early-, late-, and no-RDV groups was 7.7%, 8.8%, and 8.4%, respectively. Future hypothesis-driven studies with an appropriate adjustment for confounders are needed to formally evaluate the impact of RDV initiation timing on clinical outcomes in this high-risk, predominantly late-elderly population in Japan.<\/jats:p>","DOI":"10.3390\/v18040479","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:57:21Z","timestamp":1776758241000},"page":"479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of Remdesivir Initiation and Clinical Outcomes in Hospitalized Patients with COVID-19 Who Are at High Risk of Disease Progression in Japan: A Health Insurance Claims Database Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0207-9483","authenticated-orcid":false,"given":"Yuichiro","family":"Shindo","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Piao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, K.K., 16\/F GRAN TOKYO SOUTH TOWER, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo 100-6616, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-2012","authenticated-orcid":false,"given":"Mark","family":"Berry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94405, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Ramroth","sequence":"additional","affiliation":[{"name":"Gilead Sciences, EU, 2 Roundwood Ave., Uxbridge UB11 1AF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Gilead Sciences, K.K., 16\/F GRAN TOKYO SOUTH TOWER, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo 100-6616, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref_1","unstructured":"Mathieu, E., Ritchie, H., Rod\u00e9s-Guirao, L., Appel, C., Gavrilov, D., Giattino, C., Hasell, J., Macdonald, B., Dattani, S., and Beltekian, D. (2025, September 04). Coronavirus (COVID-19) Deaths. Our World in Data. Available online: https:\/\/ourworldindata.org\/covid-deaths."},{"key":"ref_2","unstructured":"Ministry of Health, and Labour and Welfare (MHLW) (2025, August 25). Current Status of Coronavirus Disease 2019 (COVID-19), (In Japanese)."},{"key":"ref_3","unstructured":"National Institute of Infectious Diseases (NIID), and Infectious Disease Epidemiology Center (2025, August 26). Epidemiological Profile of Severe and Fatal COVID-19 Cases, Causes of Death, and Factors Related to Severe Illnes, Available online: https:\/\/id-info.jihs.go.jp\/niid\/ja\/2019-ncov-e\/12266-2023-09-25-06-29-18.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cpt.2310","article-title":"Japan\u2019s Special Approval for Emergency System During the COVID-19 Pandemic","volume":"111","author":"Maeda","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_5","unstructured":"National Institutes of Health (2025, August 01). COVID-19 Treatment. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, Available online: https:\/\/www.emra.org\/siteassets\/emra\/documents\/nih-final-guidance-covid19treatmentguid."},{"key":"ref_6","unstructured":"Infectious Diseases Society of America (2025). IDSA Guidelines on the Treatment and Management of Patients with COVID-19, Infectious Diseases Society of America. Available online: https:\/\/www.idsociety.org\/practice-guideline\/COVID-19-guideline-treatment-and-management\/."},{"key":"ref_7","unstructured":"World Health Organization (2022). Remdesivir for COVID-19, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Therapeutics-Remdesivir-Poster_A-2022.1."},{"key":"ref_8","unstructured":"The Japanese Association for Infectious Diseases (Nihon Kansensho Gakkai), The Japanese Respiratory Society (Nihon Kokyuki Gakkai), Japanese Society of Chemotherapy (Nihon Kagaku Ryoho Gakkai), Japanese Society for Clinical Microbiology (Nihon Rinsho Biseibutsu Gakkai), and Japanese Society for Infection Prevention and Control (Nihon Kankyo Kansen Gakkai) (2025, December 05). 5-Gakkai ni yoru Shingata Koronauirusu Kansensho Shinryo no Shishin 2025 [Clinical Management Guide for COVID-19 2025: Joint Statement by Five Medical Societies]. Available online: https:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid_251017.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe COVID-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/cid\/ciad460","article-title":"Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: Findings from routine clinical practice","volume":"77","author":"Mozaffari","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cid\/ciab631","article-title":"Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with Coronavirus Disease 2019 (COVID-19)","volume":"74","author":"Wong","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e39035","DOI":"10.1097\/MD.0000000000039035","article-title":"The effect of early versus late remdesivir treatment in hospitalized mild to moderate COVID-19 patients in the omicron era: A retrospective study","volume":"103","author":"Ryu","year":"2024","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00508-024-02377-7","article-title":"The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients","volume":"136","author":"Platzer","year":"2024","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijid.2022.02.039","article-title":"Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan","volume":"118","author":"Tsuzuki","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.37737\/ace.25006","article-title":"DeSC database","volume":"7","author":"Yasunaga","year":"2025","journal-title":"Ann. Clin. Epidemiol."},{"key":"ref_17","unstructured":"Centers for Disease Control and Prevention (2025, August 27). Underlying Conditions and the Higher Risk for Severe COVID-19, Available online: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: Implications for SARS-CoV-2","volume":"19","author":"Kratzel","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_19","unstructured":"Statistics Bureau, and Ministry of Internal Affairs and Communications (2025, December 04). Current Population Estimates as of 1 October 2024, Available online: https:\/\/www.stat.go.jp\/english\/data\/jinsui\/2024np\/index.html."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/4\/479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:11:21Z","timestamp":1776849081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/4\/479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["v18040479"],"URL":"https:\/\/doi.org\/10.3390\/v18040479","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}